In vitro reactivation of replication-competent and infectious hiv-1 by histone deacetylase inhibitors

Journal of Virology

Volumn 90, Issue 4, 2016, Pages 1858-1871

  Banga, Riddhima ^a   Procopio, Francesco Andrea ^a   Cavassini, Matthias ^b   Perreau, Matthieu ^a  

^a Infectious Diseases Service   (Switzerland)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BRYOSTATIN; GIVINOSTAT; MONOCLONAL ANTIBODY CD28; MONOCLONAL ANTIBODY CD3; PANOBINOSTAT; ROMIDEPSIN; VORINOSTAT; HISTONE DEACETYLASE INHIBITOR;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CELL ISOLATION; CELL PROLIFERATION; CELL VIABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE DURATION; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IN VITRO STUDY; MALE; MEMORY T LYMPHOCYTE; MIDDLE AGED; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; VIRUS LATENCY; VIRUS REACTIVATION; VIRUS REPLICATION; CELL CULTURE; DRUG EFFECTS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; METABOLISM; PHYSIOLOGY; VIROLOGY; VIRUS ACTIVATION;

ADULT; CD4-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; FEMALE; HISTONE DEACETYLASE INHIBITORS; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; VIRUS ACTIVATION; VIRUS LATENCY; VIRUS REPLICATION;

EID: 84958073586     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02359-15     Document Type: Article

References (31)

1. Chun TW, Stuyver L, Mizell SB, Ehler LA, Mican JA, Baseler M, Lloyd AL, Nowak MA, FauciAS. 1997. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci U S A 94:13193-13197. http://dx.doi.org/10.1073/pnas.94.24.13193
2. Chun TW, Carruth L, Finzi D, Shen X, DiGiuseppe JA, Taylor H, Hermankova M, Chadwick K, Margolick J, Quinn TC, Kuo YH, Brookmeyer R, Zeiger MA, Barditch-Crovo P, Siliciano RF. 1997. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 387:183-188. http://dx.doi.org/10.1038/387183a0.
3. Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, Chaisson RE, Quinn TC, Chadwick K, Margolick J, Brookmeyer R, Gallant J, Markowitz M, Ho DD, Richman DD, Siliciano RF. 1997. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278:1295-1300. http://dx.doi.org/10.1126/science.278.5341.1295.
4. Wong JK, Hezareh M, Gunthard HF, Havlir DV, Ignacio CC, Spina CA, Richman DD. 1997. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 278:1291-1295. http://dx.doi.org/10.1126/science.278.5341.1291.
5. + T cells. Nat Med 9:727-728. http://dx.doi.org/10.1038/nm880.
6. Chomont N, El-Far M, Ancuta P, Trautmann L, Procopio FA, Yassine-Diab B, Boucher G, Boulassel MR, Ghattas G, Brenchley JM, Schacker TW, Hill BJ, Douek DC, Routy JP, Haddad EK, Sekaly RP. 2009. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med 15:893-900. http://dx.doi.org/10.1038/nm.1972.
7. Deeks SG. 2012. HIV: shock and kill. Nature 487:439-440. http://dx.doi.org/10.1038/487439a.
8. Wightman F, Ellenberg P, Churchill M, Lewin SR. 2012. HDAC inhibitors in HIV. Immunol Cell Biol 90:47-54. http://dx.doi.org/10.1038/icb .2011.95.
9. Rasmussen TA, Schmeltz Søgaard O, Brinkmann C, Wightman F, Lewin SR, Melchjorsen J, Dinarello C, Ostergaard L, Tolstrup M. 2013. Comparison of HDAC inhibitors in clinical development: effect on HIV production in latently infected cells and T-cell activation. Hum Vaccin Immunother 9:993-1001. http://dx.doi.org/10.4161/hv.23800.
10. + T cells. J Antimicrob Chemother 69:28-33. http://dx.doi.org/10.1093/jac/dkt338.
11. Archin NM, Espeseth A, Parker D, Cheema M, Hazuda D, Margolis DM. 2009. Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid. AIDS Res Hum Retroviruses 25: 207-212. http://dx.doi.org/10.1089/aid.2008.0191.
12. Sahu GK, Cloyd MW. 2011. Latent HIV in primary T lymphocytes is unresponsive to histone deacetylase inhibitors. Virol J 8:400. http://dx.doi.org/10.1186/1743-422X-8-400.
13. + T cells. Retrovirology 8:80. http://dx.doi.org/10.1186/1742-4690-8-80.
14. Blazkova J, Chun TW, Belay BW, Murray D, Justement JS, Funk EK, Nelson A, Hallahan CW, Moir S, Wender PA, Fauci AS. 2012. Effect of histone deacetylase inhibitors on HIV production in latently infected, resting CD4(+) T cells from infected individuals receiving effective antiretroviral therapy. J Infect Dis 206:765-769. http://dx.doi.org/10.1093/infdis/jis412.
15. Bullen CK, Laird GM, Durand CM, Siliciano JD, Siliciano RF. 2014. New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo. Nat Med 20:425-429. http://dx.doi.org/10.1038/nm.3489.
16. + T cells from patients on suppressive antiretroviral therapy. Proc Natl Acad Sci U S A 111:7078-7083. http://dx.doi.org/10.1073/pnas.1402873111.
17. Ylisastigui L, Archin NM, Lehrman G, Bosch RJ, Margolis DM. 2004. Coaxing HIV-1 from resting CD4 T cells: histone deacetylase inhibition allows latent viral expression. AIDS 18:1101-1108. http://dx.doi.org/10.1097/00002030-200405210-00003.
18. Laird GM, Bullen CK, Rosenbloom DI, Martin AR, Hill AL, Durand CM, Siliciano JD, Siliciano RF. 2015. Ex vivo analysis identifies effective HIV-1 latency-reversing drug combinations.J Clin Invest 125:1901-1912. http://dx.doi.org/10.1172/JCI80142.
19. + T cells after multiple doses of vorinostat. J Infect Dis 210:728-735. http://dx.doi.org/10.1093/infdis/jiu155.
20. Rasmussen TA, Tolstrup M, Brinkmann CR, Olesen R, Erikstrup C, Solomon A, Winckelmann A, Palmer S, Dinarello C, Buzon M. 2014. Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial. Lancet HIV 1:e13-e21. http://dx.doi.org/10.1016/S2352-3018(14)70014-1.
21. Dar RD, Hosmane NN, Arkin MR, Siliciano RF, Weinberger LS. 2014. Screening for noise in gene expression identifies drug synergies. Science 344:1392-1396. http://dx.doi.org/10.1126/science.1250220. 22. Perreau M, Kremer EJ. 2005. Frequency, proliferation, and activation of human memory T cells induced by a nonhuman adenovirus. J Virol 79: 14595-14605. http://dx.doi.org/10.1128/JVI.79.23.14595-14605.2005.
22. Perreau M, Kremer EJ. 2005. Frequency, proliferation, and activation of human memory T cells induced by a nonhuman adenovirus. J Virol 79: 14595-14605. http://dx.doi.org/10.1128/JVI.79.23.14595-14605.2005.
23. Vandergeeten C, Fromentin R, Merlini E, Lawani MB, DaFonseca S, Bakeman W, McNulty A, Ramgopal M, Michael N, Kim JH, Ananworanich J, Chomont N. 2014. Cross-clade ultrasensitive PCR-based assays to measure HIV persistence in large-cohort studies. J Virol 88: 12385-12396. http://dx.doi.org/10.1128/JVI.00609-14.
24. + T-cells than previously recognized, abstr 174LB. Conf Retrovir Opportunistic Infect, 3 to 6 March, Atlanta, GA.
25. Hu Y, Smyth GK. 2009. ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. J Immunol Methods 347:70-78. http://dx.doi.org/10.1016/j.jim.2009.06.008.
26. Archin NM, Liberty AL, Kashuba AD, Choudhary SK, Kuruc JD, Crooks AM, Parker DC, Anderson EM, Kearney MF, Strain MC, Richman DD, Hudgens MG, Bosch RJ, Coffin JM, Eron JJ, Hazuda DJ, Margolis DM. 2012. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 487:482-485. http://dx.doi.org/10.1038/nature11286.
27. + T cells. PLoS Pathog 7:e1002288. http://dx.doi.org/10.1371/journal.ppat.1002288.
28. Cloherty G, Swanson P, Lucic D, Dieckhaus K, Anthony P, Cataline P, Herman C, Hackett J, Jr, Skolnik PR, Chirch L. 2014. Clinical implications of elevated HIV-1 viral load results obtained from samples stored frozen in Vacutainer plasma preparation tubes. J Virol Methods 204:91-92. http://dx.doi.org/10.1016/j.jviromet.2014.01.025.
29. Ho YC, Shan L, Hosmane NN, Wang J, Laskey SB, Rosenbloom DI, Lai J, Blankson JN, Siliciano JD, Siliciano RF. 2013. Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. Cell 155:540-551. http://dx.doi.org/10.1016/j.cell.2013.09.020.
30. Furlan A, Monzani V, Reznikov LL, Leoni F, Fossati G, Modena D, Mascagni P, Dinarello CA. 2011. Pharmacokinetics, safety and inducible cytokine responses during a phase 1 trial of the oral histone deacetylase inhibitor ITF2357 (givinostat). Mol Med 17:353-362. http://dx.doi.org/10.2119/molmed.2011.00020.
31. Søgaard OS, Graversen ME, Leth S, Olesen R, Brinkmann CR, Nissen SK, Kjaer AS, Schleimann MH, Denton PW, Hey-Cunningham WJ, Koelsch KK, Pantaleo G, Krogsgaard K, Sommerfelt M, Fromentin R, Chomont N, Rasmussen TA, Østergaard L, Tolstrup M. 2015. The depsipeptide romidepsin reverses HIV-1 latency in vivo. PLoS Pathog 11: e1005142. http://dx.doi.org/10.1371/journal.ppat.1005142.